Founded in November 2020 by Aridni Shah and Trisha Chatterjee in Bengaluru, immunitoAI operates at the intersection of biotechnology and AI. Its core product is a generative AI platform that creates entirely new antibody sequences for any target antigen, shrinking discovery timelines from four–five years to roughly 11–12 months. The company maintains an in-house wet lab to validate and test the computer-generated antibodies. immunitoAI plans to earn revenue through three channels: selling proprietary antibody IP, undertaking custom antibody development projects for pharmaceutical clients, and eventually offering end-to-end drug development as a fully integrated pharma company. The startup is currently pre-revenue, but management projects that a single custom-developed antibody could fetch about USD 300 million plus royalties. By reducing discovery costs and timelines by more than 50%, the platform aims to accelerate targeted therapies for diseases such as cancer and autoimmune disorders. The newly raised capital will fund the development of trial-ready antibodies for specific diseases, advancing the company toward commercialization.

Total raised

$7M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2025